A drug already set to transform care for men with advanced prostate cancer has impressive benefits for men with earlier-stage disease too, a major new clinical trial shows. Abiraterone, discovered at The Institute of Cancer Research, London*, was approved last May by NICE for use on the NHS to treat prostate cancer that has stopped responding to standard hormone therapies and docetaxel chemotherapy...
More...
More...